Skip to main content

Table 2 Sensitivities and specificities for individual markers and combination of markers

From: A panel of DNA methylation markers reveals extensive methylation in histologically benign prostate biopsy cores from cancer patients

 

Cancer cores

Control cores

Non cancer cores from cases

Marker

No. Pos/No. cases

Sensitivity

95% CI

No. Neg/No. controls

Specificity

95% CI

No. Pos/No. cases

Sensitivity

95% CI

CYBA

22/37

0.59

(0.44, 0.75)

64/67

0.96

(0.91, 1.00)

5/37

0.14

(0.02, 0.25)

HOXB5

31/37

0.84

(0.72, 0.96)

56/67

0.84

(0.75, 0.92)

24/36

0.67

(0.51, 0.82)

RASSF1

33/37

0.89

(0.79, 0.99)

55/67

0.82

(0.73, 0.91)

16/37

0.43

(0.27, 0.59)

SOCS3

27/37

0.73

(0.59, 0.87)

61/67

0.91

(0.84, 0.98)

17/36

0.47

(0.31, 0.64)

GRASP

22/37

0.59

(0.44, 0.75)

64/67

0.96

(0.91, 1.00)

1/37

0.03

(0.00, 0.08)

HAPLN3

27/37

0.73

(0.59, 0.87)

63/67

0.94

(0.88, 1.00)

11/37

0.30

(0.15, 0.44)

SLC16A5

11/37

0.30

(0.15, 0.44)

64/67

0.96

(0.91, 1.00)

2/37

0.05

(0.00, 0.13)

HOXD9

34/37

0.92

(0.83, 1.01)

43/65

0.66

(0.55, 0.78)

29/36

0.81

(0.68, 0.93)

ARHGEF10

8/37

0.22

(0.08, 0.35)

62/67

0.93

(0.86, 0.99)

7/37

0.19

(0.06, 0.32)

KLK10

14/37

0.38

(0.22, 0.53)

67/67

1.00

--

1/37

0.03

(0.00, 0.08)

GSTP1

25/36

0.69

(0.54, 0.84)

64/67

0.96

(0.91, 1.00)

10/37

0.27

(0.13, 0.41)

RASSF5

28/37

0.76

(0.62, 0.90)

61/67

0.91

(0.84, 0.98)

21/37

0.57

(0.41, 0.73)

MOXD1

12/37

0.32

(0.17, 0.48)

61/67

0.91

(0.84, 0.98)

6/37

0.16

(0.04, 0.28)

RARB

25/37

0.68

(0.52, 0.83)

64/67

0.96

(0.91, 1.00)

4/37

0.11

(0.01, 0.21)

GPX7b

16/37

0.43

(0.27, 0.59)

64/67

0.96

(0.91, 1.00)

5/37

0.14

(0.02, 0.25)

APC

27/36

0.75

(0.61, 0.89)

61/67

0.91

(0.84, 0.98)

12/35

0.34

(0.19, 0.50)

GFRA2

13/36

0.36

(0.20, 0.52)

64/67

0.96

(0.91, 1.00)

5/35

0.14

(0.03, 0.26)

LOXL2

11/36

0.31

(0.16, 0.46)

65/67

0.97

(0.93, 1.00)

5/35

0.14

(0.03, 0.26)

NEUROG3

18/36

0.50

(0.34, 0.66)

64/67

0.96

(0.91, 1.00)

6/35

0.17

(0.05, 0.30)

PTGS2

4/36

0.11

(0.01, 0.21)

65/67

0.97

(0.93, 1.00)

10/35

0.29

(0.14, 0.44)

ADCY4

36/37

0.97

(0.92, 1.03)

56/67

0.84

(0.75, 0.92)

20/37

0.54

(0.38, 0.70)

CXCL14

27/37

0.73

(0.59, 0.87)

63/67

0.94

(0.88, 1.00)

10/37

0.27

(0.13, 0.41)

HEMK1

15/37

0.41

(0.25, 0.56)

60/67

0.90

(0.82, 0.97)

2/37

0.05

(0.00, 0.13)

KIFC2

22/37

0.59

(0.44, 0.75)

67/67

1.00

--

8/37

0.22

(0.08, 0.35)

3 of 24

37/37

1.00

--

46/67

0.69

(0.58, 0.80)

31/37

0.84

(0.72, 0.96)

4 of 24

37/37

1.00

--

56/67

0.84

(0.75, 0.92)

23/37

0.62

(0.47, 0.78)

5 of 24

37/37

1.00

--

65/67

0.97

(0.93, 1.01)

23/37

0.62

(0.47, 0.78)

6 of 24

36/37

0.97

(0.92, 1.03)

66/67

0.99

(0.96, 1.01)

19/37

0.51

(0.35, 0.67)

7 of 24

36/37

0.97

(0.92, 1.03)

66/67

0.99

(0.96, 1.01)

18/37

0.49

(0.33, 0.65)

8 of 24

36/37

0.97

(0.92, 1.03)

67/67

1.00

--

15/37

0.41

(0.25, 0.56)

9 of 24

35/37

0.95

(0.87, 1.02)

67/67

1.00

--

11/37

0.30

(0.15, 0.44)

10 of 24

30/37

0.81

(0.68, 0.94)

67/67

1.00

--

11/37

0.30

(0.15, 0.44)

11 of 24

27/37

0.73

(0.59, 0.87)

67/67

1.00

--

5/37

0.14

(0.02, 0.25)

12 of 24

25/37

0.68

(0.52, 0.83)

67/67

1.00

--

5/37

0.14

(0.02, 0.25)

13 of 24

20/37

0.54

(0.38, 0.70)

67/67

1.00

--

3/37

0.08

(0.00, 0.17)

14 of 24

17/37

0.46

(0.30, 0.62)

67/67

1.00

--

2/37

0.05

(0.00, 0.13)

15 of 24

15/37

0.41

(0.25, 0.56)

67/67

1.00

--

1/37

0.03

(0.00, 0.08)

16 of 24

14/37

0.38

(0.22, 0.53)

67/67

1.00

--

0/37

0.00

--

17 of 24

11/37

0.30

(0.15, 0.44)

67/67

1.00

--

0/37

0.00

--

18 of 24

7/37

0.19

(0.06, 0.32)

67/67

1.00

--

0/37

0.00

--

19 of 24

7/37

0.19

(0.06, 0.32)

67/67

1.00

--

0/37

0.00

--

20 of 24

3/37

0.08

(0.00, 0.17)

67/67

1.00

--

0/37

0.00

--

  1. Shows the estimated sensitivity and specificity associated with each marker (where a marker test is defined as the presence (>0 concentration) or absence (0 concentration) of the particular marker). The column preceding sensitivity yields the number of “positive tests” and the number of “true cases”. Similarly, the column preceding specificity yields the number of “negative tests” and the number of “true controls”. Similarly for the non-cancer cores from cases, the estimated sensitivity associated with each marker and the sensitivity associated with the total number of markers were calculated using the non-CA core with the highest number of positive markers from each case.
Back to article page

Biomarker Research

ISSN: 2050-7771

Contact us